Drug Type Degrader-antibody conjugates, Molecular glue−antibody conjugate |
Synonyms MAC-8001 |
Target |
Action inhibitors |
Mechanism CD276 inhibitors(CD276 antigen inhibitors), KRAS inhibitors(GTPase KRas inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Neoplasms | Preclinical | China | 20 Apr 2026 |






